Chinese pharmaceutical company Hengrui has entered into a global collaboration and licensing agreement with US giant Bristol Myers Squibb (BMS). The deal, valued at up to US$15.2 billion, involves the development of 13 oncology, haematology, and immunology programs. Hengrui's shares saw a significant increase following the announcement of this significant partnership. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT This partnership focuses on drug innovation and development, with potential implications for future pharmaceutical advancements.
RANK_REASON This is a significant business partnership between two major pharmaceutical companies with a substantial deal value. [lever_c_demoted from significant: ic=1 ai=0.1]
